The early clinical data above suggest that BTK degraders may be an effective drug class for the treatment of CLL, especially valuable for the patients with ‘double refractory’ CLL/SLL who have limited available therapeutic options. Here, BTK is linked to B-cell chronic lymphocytic leukemia.